nytimes.com / .nytimes-com-health / Page 2

The babies were part of a vaccine trial for a respiratory virus in the 1960s and died shortly after. Their families said they had been unaware of the trial until recently.

As predictive medicine advances, legal scholars warn that decades-old federal guidelines could set up a potential clash between your genes and your job.

Most people recover from the infection, but it poses great risks for those who don't. A new drug may cure 1 in 5 of these patients.

Drew Altman, who transformed KFF from a little-known family foundation to a major source of U.S. health policy research, will step down at the end of the year.

The types of Ebola and hantavirus panicking officials are very different from the species identified decades ago, raising new questions about how to respond.

In past outbreaks, Americans exposed to the virus were sent home to be treated in state-of-the-art facilities. The Trump administration has already flown some U.S. citizens to Europe for treatment.

The drugmaker said it would spend up to $4 billion to acquire small companies exploring vaccines for shingles, Epstein-Barr virus and other pathogens.

Lenacapavir, which protects people from H.I.V. infection with twice-yearly shots, is arriving in a country where the health system has been hollowed out by American aid cuts.

A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point to something "curative," one expert said.

The deadly virus has spread alarmingly in Congo for months. Only now is the response taking shape.